Pharmacyclics I Janssen- COMMERCIAL

Sunnyvale,  CA 
United States
https://www.imbruvicahcp.com/
  • Booth: 3107a

IMBRUVICA® is approved for adults with CLL, SLL, and WM. WARNINGS AND PRECAUTIONS: Hemorrhage, infections, cytopenias, cardiac arrhythmias and cardiac failure, hypertension, second primary malignancies, tumor lysis syndrome, and embryo-fetal toxicity. ADVERSE REACTIONS: The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%)*, diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%)*, rash (35.8%), anemia (35.0%)*, and bruising (32.0%). *Treatment-emergent decreases (all grades) were based on laboratory measurements. Please see the full Important Safety Information in the video below and the full Prescribing Information available at https://imbruvica.com/prescribing-information.

Brands: https://events.jspargo.com/ASCO21/CUSTOM/IMBRUVICA_ASCO_BANNER_2_LOGO_04_21_21.png


 Show Specials


 Press Releases

  • (Apr 22, 2021)
    https://events.jspargo.com/ASCO21/CUSTOM/PRC-08176_Media%20PDF.pdf